Unlock 20% Off Global Market Reports Using Code ONLINE20 – Stay Informed on Trade Policies, Market Growth, and Key Disruptors
What Are the Long-Term Growth Opportunities and Market Size Outlook for the Omics-Based Clinical Trials Market?
The omics-based clinical trials market size has grown strongly in recent years. It will grow from $29.10 billion in 2024 to $31.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to the rising number of clinical trials involving omics technologies, the growing emphasis on translational research, increasing government support and funding, the growing availability of biobanks and biospecimens, and increasing awareness about the benefits of precision therapies.
The omics-based clinical trials market size is expected to see strong growth in the next few years. It will grow to $44.08 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising adoption of multi-omics approaches, growing prevalence of chronic and rare diseases, rising investment in genomic research and biotechnology, and growing focus on biomarker discovery. Major trends in the forecast period include advancements in next-generation sequencing (NGS) technologies, integration of artificial intelligence with omics platforms, technological developments in bioinformatics tools, advancements in proteomics and metabolomics platforms, and integration of multi-omics data.
Claim your free report sample now:
What Are the Key Factors Contributing to Omics-Based Clinical Trials Market Growth?
The increasing demand for personalized medicine is expected to propel the growth of the omics-based clinical trials market going forward. Personalized medicine refers to a medical approach that tailors disease prevention, diagnosis, and treatment to the individual characteristics of each patient. Personalized medicine demand is rising due to advances in genomic technologies that allow for faster, cost-effective analysis of individual genetic profiles to guide targeted treatments. Omics-based clinical trials support personalized medicine by enabling the identification of individual genetic, proteomic, and metabolic profiles, thereby allowing for more targeted and effective treatment strategies tailored to each patient. For instance, in February 2023, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2022, the approval of 12 new personalized medicines represented approximately 34% of all newly approved therapies, indicating a substantial increase from previous years. Therefore, the increasing demand for personalized medicine is driving the growth of the omics-based clinical trials market.
What Are the Core Segments Shaping the Omics-Based Clinical Trials Market Landscape?
The omics-based clinical trials market covered in this report is segmented
1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories
Subsegments:
1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping
3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis
4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling
What Are the Notable Trends in the Omics-Based Clinical Trials Market by Product, Application, and Region?
Major companies operating in the omics-based clinical trials market are focusing on innovative solutions, such as HiFi sequencing technology, to enhance the accuracy, speed, and depth of multi-omics data analysis, ultimately improving trial outcomes and personalized treatment strategies. HiFi sequencing refers to a next-generation sequencing (NGS) technology that produces long, highly accurate reads using circular consensus sequencing (CCS), enabling comprehensive and precise analysis of genomes, transcriptomes, and epigenomes. For instance, in October 2024, Pacific Biosciences of California Inc., a US-based biotechnology company, in collaboration with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, launched a state-of-the-art lab to accelerate genomics innovation in Singapore with cutting-edge long-read sequencing technology. The facility enables researchers to conduct advanced genomic studies with greater precision and speed. It supports a wide range of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. The lab also fosters collaboration among global scientists and local institutions, aiming to accelerate discoveries in personalized medicine, rare disease diagnostics, and precision oncology. Additionally, it offers training programs and shared access to high-throughput sequencing infrastructure, promoting capacity-building and innovation within the Asia-Pacific region.
Which Players Dominate the Omics-Based Clinical Trials Market Landscape?
Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, and BioAro Inc.
Get the full omics-based clinical trials market report here:
What Are the Regional Insights for the Omics-Based Clinical Trials Market Forecast?
North America was the largest region in the omics-based clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment